PubMed Health⌕ Search

PubMed · 7372872

Pseudomembranous colitis.

Abstract

A case of pseudomembranous colitis is reported in which computed tomography (CT) played an important role in the diagnosis and differentiation from other causes of fever and abdominal pain. It is important to look for CT evidence of primary bowel disease when scans are performed for possible abdominal abscess, since these two conditions may present similar clinical features.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P C Goodman, M P Federle. 1980. Pseudomembranous colitis.. https://doi.org/10.1097/00004728-198006000-00017

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Long-term results from laparoscopic common bile duct exploration.

BACKGROUND: The aim of this study was to evaluate the long-term results after laparoscopic common bile duct exploration (LCBDE). METHODS: A retrospective review of 175 consecutive patients who underwent attempted LCBDE between 1992 and 1999 was conducted. Laparoscopic transcystic exploration was accomplished in 110 patients and laparoscopic choledochotomy in 52 patients. Conversion to an open common bile duct exploration was required for 13 patients (7.4%). Retained common bile duct stones occurred in eight patients (4.6%). The 30-day postoperative morbidity was 6.9%, and there was no 30-day mortality. All the patients (alive and localized) received a questionnaire evaluating long-term results. RESULTS: Of the 175 patients, 169 (4 unrelated deaths and 2 patients lost to follow-up evaluation) received and 152 (90%) returned the questionnaire. The follow-up period ranged from 6 to 72 months (median, 36 months). One patient developed recurrent common bile duct stones. There were no signs or evidence of common bile duct stricture in any patient. CONCLUSION: The LCBDE procedure can be performed without increased risk of late bile duct complications.

Abscess↗

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.

Bacterial enoyl-ACP reductase (FabI) is responsible for catalyzing the final step of bacterial fatty acid biosynthesis and is an attractive target for the development of novel antibacterial agents. Previously we reported the development of FabI inhibitor 4 with narrow spectrum antimicrobial activity and in vivo efficacy against Staphylococcus aureus via intraperitoneal (ip) administration. Through iterative medicinal chemistry aided by X-ray crystal structure analysis, a new series of inhibitors has been developed with greatly increased potency against FabI-containing organisms. Several of these new inhibitors have potent antibacterial activity against multidrug resistant strains of S. aureus, and compound 30 demonstrates exceptional oral (po) in vivo efficacy in a S. aureus infection model in rats. While optimizing FabI inhibitory activity, compounds 29 and 30 were identified as having low micromolar FabK inhibitory activity, thereby increasing the antimicrobial spectrum of these compounds to include the FabK-containing pathogens Streptococcus pneumoniae and Enterococcus faecalis. The results described herein support the hypothesis that bacterial enoyl-ACP reductases are valid targets for antibacterial agents.

Abscess↗